Amplia Therapeutics Ltd.ASX: ATX

Amplia Announces Appointment of Brett Carter to Board

· Issued by Amplia Therapeutics Ltd. via GlobeNewswire

Summary by 6ix AI

Amplia Therapeutics Limited appointed Mr Brett Carter to its Board of Directors as a non-executive director (a board member who is not part of management), effective from July 6, 2026.

Key details

  • Mr Carter is a biopharmaceutical executive with more than 25 years' global experience across oncology drug development, corporate strategy and business development, including 11 years with GSK in London and a role as CEO of the Cancer Therapeutics Cooperative Research Centre, where Amplia's drug assets were discovered.

6ix AI wrote this summary from the release below and checked it against the release.

Melbourne, Australia, July 07, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX, OTCQB:INNMF), ("Amplia" or the "Company"), is pleased to announce the appointment of Mr Brett Carter to the Board of Directors as non-executive director, effective from 6 July 2026.

Amplia Board chair Ms Jane Bell AM commented, "I am delighted to welcome Brett to the Board at this exciting time in the Company's development. His extensive experience in the structuring and negotiation of licensing, acquisition, investment and financing transactions across global pharmaceutical markets will be critical as Amplia's lead drug narmafotinib progresses into later stage development."

Mr Carter is an experienced biopharmaceutical executive with more than 25 years' global experience across oncology drug development, corporate strategy and business development. Mr Carter spent 11 years with GSK in London, including as a director in the company's global corporate transactions team, where he led and supported major licensing, acquisition, investment and divestment transactions across Europe, Asia and the United States. Mr Carter was subsequently CEO of the Cancer Therapeutics Cooperative Research Centre, where Amplia's drug assets were discovered, and while there was involved in the licensing of an oncology program to Pfizer in a deal valued up to $670 million.

Mr Carter holds an MBA from London Business School and a BSc from RMIT University and is a graduate of the Australian Institute of Company Directors. He is currently COO of Melbourne-based Medicines Development for Global Health, a director of privately-held biotech Greywolf Therapeutics Australia, and strategic adviser to various Australian life science companies.

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

Investor Contact:
Dr Chris Burns
Chief Executive Officer
[email protected]

U.S. Contact:
Robert Giordano
[email protected]
+1 917 327 3938

Media Contact:
H^CK Director, Haley Chartres
[email protected]
+61 411 235 692

U.S. Media:
[email protected]

About Amplia Therapeutics Limited

Amplia Therapeutics Ltd. on 6ix

Earlier from Amplia Therapeutics

Later from Amplia Therapeutics

All Amplia Therapeutics news releases